Astellas Pharma, Inc.

Most Recent

  • uploads///Voya Japan TOPIX Index Portfolio Class A
    Macroeconomic Analysis

    How the Voya Japan TOPIX Index Portfolio Class A Fared in September 2015

    The Voya Japan TOPIX Index Portfolio fell by 6.7% in September 2015 from the previous month.

    By David Ashworth
  • Macroeconomic Analysis

    Stock Selection Saves the Nuveen Tradewinds Japan Fund – A

    The Nuveen Tradewinds Japan Fund – A (NTJAX) fell 4.4% in August from a month ago. In the three-month period ended August 31, it fell 2.1%, the third least faller.

    By David Ashworth
  • uploads///drugs _
    Company & Industry Overviews

    Why Scynexis Stock Rose 16.4% Yesterday

    Yesterday, Scynexis (SCYX) stock rose 16.4% on the announcement of positive data from its Phase 2b clinical trial of SCY-078.

    By Sarah Collins
  • uploads///HAC
    Company & Industry Overviews

    How Is Merck’s Hospital Acute Care Segment Positioned?

    Merck & Company’s (MRK) Bridion generated revenue of $204 million in Q1 2018 compared to $148 million in Q1 2017.

    By Daniel Collins
  • uploads///Lupron
    Company & Industry Overviews

    Updates on AbbVie’s AndroGel, Lupron, and Kaletra

    In 4Q17, AbbVie’s (ABBV) AndroGel reported revenue of $140 million, compared with $174 million in 4Q16, reflecting a ~20% decline YoY (year-over-year) and a ~5% decline quarter-over-quarter.

    By Daniel Collins
  • uploads///FGEN
    Company & Industry Overviews

    Understanding FibroGen’s Research Pipeline

    Apart from Roxadustat, other products in FibroGen’s pipeline include Pamrevlumab (or FG-3019) and FG-5200.

    By Kenneth Smith
  • uploads///Immunology
    Company & Industry Overviews

    A Look at Novartis’s Immunology and Dermatology Segment’s Performance

    In 4Q17, Novartis’s Immunology and Dermatology segment generated revenues of $1.2 billion, ~30% growth on a year-over-year (or YoY) basis and ~9% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Invanz and Cancidas
    Company & Industry Overviews

    How Did Merck’s Invanz and Cancidas Perform in 2017?

    In 4Q17, Merck’s (MRK) Invanz generated revenues of $157 million, which represents a ~3% rise on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Branded Rx prod
    Company & Industry Overviews

    Behind Valeant’s Branded Drugs: Other 3Q17 Performances

    In 3Q17, Valeant’s (VRX) Arestin reported revenues of $26 million, which was ~7% lower on a YoY (year-over-year) basis and 7% lower quarter-over-quarter.

    By Daniel Collins
  • uploads///Zytiga
    Company & Industry Overviews

    How Johnson & Johnson’s Zytiga Performed in 3Q17

    In 3Q17, Johnson & Johnson’s (JNJ) Zytiga generated revenues of $669 million, which reflected ~15% growth on a year-over-year (or YoY) basis and 20% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Synergy Pharmas Trulance performance
    Company & Industry Overviews

    An Overview of Trulance: Synergy Pharmaceuticals’ First Commercialized Drug

    Since its launch, Synergy’s (SGYP) Trulance sales have been steadily rising. In 3Q17, more than 25,000 prescriptions were filled for the drug.

    By Kenneth Smith
  • uploads///Immunology
    Company & Industry Overviews

    How Novartis’s Immunology and Dermatology Portfolio Looks after 3Q17

    In 3Q17, Novartis’s (NVS) Neoral generated revenues of ~$126 million, which represents a ~3% YoY (year-over-year) fall and a 2% QoQ fall.

    By Daniel Collins
  • uploads///Lupron Revenues
    Company & Industry Overviews

    Why Lupron Could Continue to Generate Steady Revenue

    In 2016, AbbVie’s (ABBV) Lupron generated revenue of $821 million, a slight fall of 0.6% year-over-year (or YoY). In 1Q17, Lupron reported revenue of ~$194 million.

    By Daniel Collins
  • Company & Industry Overviews

    Depressed Consumer Spending Hurt the Fidelity Advisor Overseas Fund

    The Fidelity Advisor Overseas Fund – Class A (FAOAX) has emerged as a below-average performer in YTD 2016 among the 12 funds chosen for this review.

    By David Ashworth
  • uploads///Portfolio Breakdown of the FAOAX
    Fund Managers

    What’s the Sector Composition of the Fidelity Advisor Overseas Fund?

    The Fidelity Advisor Overseas Fund invests at least 80% of its net assets in common stocks of non-US issuers.

    By David Ashworth
  • uploads///Portfolio Breakdown of the TGRAX
    Fund Managers

    How Is the Invesco Pacific Growth Fund Allocating Its Portfolio?

    TGRAX is quite balanced as far as allocation in its top three sectors is concerned.

    By David Ashworth
  • Company & Industry Overviews

    Why 2016 Has Been Forgettable for the BlackRock Pacific Fund

    Financials have contributed the lion’s share of the BlackRock Pacific Fund – Investor A Shares’ (MDPCX) poor showing in 2016 YTD.

    By David Ashworth
  • uploads///Portfolio Breakdown of the FAOAX
    Fund Managers

    The Fidelity Advisor Overseas Fund’s Portfolio Moves in YTD 2016

    The Fidelity Advisor Overseas Fund’s (FAOAX) top sectoral bet is the consumer discretionary sector, which forms one-fourth of the fund’s total assets.

    By David Ashworth
  • uploads///Commonwealth Japan Fund
    Company & Industry Overviews

    Healthcare Stocks Save the Day for CNJFX

    Financials were the biggest negative contributors to CNJFX’s total returns in the first four months of 2016.

    By David Ashworth
  • uploads///non GAAP revenue
    Earnings Report

    The Story behind Medivation’s Rising Collaboration Revenue

    Medivation (MDVN) earned collaboration revenue from Xtandi’s US and non-US sales along with upfront and milestone payments.

    By Jillian Dabney
  • uploads///reimbursement approval
    Company & Industry Overviews

    How Are Drugs Priced in Japan?

    The NHI revises drug prices every two years. During fiscal 2016, a 6.8% reduction in drug prices is expected.

    By Jillian Dabney
  • uploads///New drug development and approval
    Company & Industry Overviews

    What’s the Drug Approval Process in Japan?

    The drug approval process in Japan includes a sequence of non-clinical studies, clinical studies followed by approval review, and post-marketing surveillance.

    By Jillian Dabney
  • uploads///FAOAXs Top Ten Invested Geographies
    Fund Managers

    What You Should Know about the Fidelity Advisor Overseas Fund

    The Fidelity Advisor Overseas Fund – Class A (FAOAX) was incepted in September 1996 and has an expense ratio of 1.4%.

    By David Ashworth
  • uploads///T Rowe Price International Stock Fund
    Company & Industry Overviews

    PRITX’s Recent Performance: What Does This Mean for Investors?

    The T. Rowe Price International Stock Fund (PRITX) has been in existence since May 1980.

    By David Ashworth
  • uploads///TGRAXs Top Ten Invested Geographies
    Fund Managers

    Get Your Essentials on the Invesco Pacific Growth Fund (TGRAX)

    The Invesco Pacific Growth Fund, under normal circumstances, will invest “at least 80% of its net assets in securities of issuers in the Pacific region.”

    By David Ashworth
  • uploads///CASAXs Top Ten Invested Geographies
    Fund Managers

    Meet the Columbia Pacific/Asia Fund (CASAX)

    The Columbia Pacific/Asia Fund (CASAX) aims to invest 80% of its net assets in equity securities of companies “located in Asia and the Pacific Basin.

    By David Ashworth
  • uploads///Portfolio Breakdown of the PRJPX
    Fund Managers

    A Portfolio Scan of the T. Rowe Price Japan Fund in 2015

    The T. Rowe Price Japan Fund (PRJPX) is well diversified with 78 holdings as of December 2015. It was managing assets worth $330.08 million at the end of December.

    By David Ashworth
  • uploads///Portfolio Breakdown of the FJPNX
    Fund Managers

    A Portfolio Scan of the Fidelity Japan Fund in 2015

    The Fidelity Japan Fund’s (FJPNX) assets were spread across 86 securities as of December 2015 and it was managing $545.18 million in assets.

    By David Ashworth
  • uploads///ecefafcfffbdebfa
    Company & Industry Overviews

    Market Response to Xalkori’s Label Update

    Observing the changes in Pfizer’s stock price after Xalkori’s label update by the European Commission shows that the stock price rose by ~2.8%.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Pfizer’s Xalkori Approved by the European Commission

    Pfizer’s oncology drug Xalkori, also termed Crizotinib, was approved for label expansion and label update by the European Commission on November 25.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    Insight on Profile 1014: Phase III Study for Xalkori

    Profile 1014 is the Phase III study for Xalkori, an ALK inhibitor. As per Pfizer’s press release, study was a randomized, and involved 343 patients.

    By Mike Benson
  • uploads///Portfolio Break down of the IJIAX
    Macroeconomic Analysis

    The Voya Japan TOPIX Index Portfolio Class A (IJIAX): Historical Overview

    The Voya Japan TOPIX Index Portfolio Class A is an index fund, not an actively managed mutual fund, so it necessarily tracks its benchmark index.

    By David Ashworth
  • uploads///Portfolio Break down of the FJPNX
    Macroeconomic Analysis

    Assessing the Fidelity Japan Fund (FJPNX): Historical Overview

    The Fidelity Japan Fund invests at least 80% of its assets in securities of Japanese issuers and other investments that are tied economically to Japan.

    By David Ashworth
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.